The company said it completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, on March 24, 2026. The purchase price is $8.875 billion in cash, and additional earnout and other payments that depend heavily on performance may also be made.

1. 01

   The company said it completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, on March 24, 2026. The purchase price is $8.875 billion in cash, and additional earnout and other payments that depend heavily on performance may also be made.

2. 02

   The company said that, apart from the cash paid at closing, it agreed to pay $125 million in January 2027 and up to $400 million in earn-out payments based on the business's performance in 2026 and 2027.

3. 03

   Thermo Fisher said the acquisition is expected to contribute $0.45 to adjusted EPS in the first year after closing. It also continues to expect to realize about $175M of adjusted operating income from synergies by year 5 after closing, primarily from revenue synergies.

4. 04

   The company said the Clario business will become part of its Laboratory Products and Biopharma Services segment. It also said the Clario platform has supported about 70% of FDA and EMA novel drug approvals over the past 10 years.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.